Funding
Period | Funding Agency | Titel | Principal Investigator |
2023-2027 | EU | ECP induction therapy after lung transplantation | Thomas Wekerle |
2023 | Research Platform Transplantation (Medical University of Vienna) | Not all sensitization events are equal - A specific experimental approach to investigate long-lived plasma cells as potential therapeutic target in pregnancy induced allo-sensitization | Moritz Muckenhuber |
2022-2023 | Astrazeneca | Observational Study on the Clinical Use of EVUSHELD (AZD7442) in Austria | Thomas Wekerle |
2022 | Research Platform Transplantation (Medical University of Vienna) | scRNAseq-based analysis of Treg-NK cell interactions critical for chimerism-based transplantation tolerance | Konstantinos Mengrelis |
2023-2024 | Medical-scientific fund of the Mayor of Vienna | Adoptive cell therapy for immunomodulation in organ transplantation | Thomas Wekerle |
2021 - 2023 | Medical-scientific fund of the Mayor of Vienna | Rethinking immunosuppressive induction - a safe path towards costimulation blockade-based maintenance in solid organ transplantation | Moritz Muckenhuber |
2020 - 2024 | Danube Allergy Research Cluster (DARC) - Towards Cure of Allergy ( funded by the Federal Government of Lower Austria) | Cell therapy approaches for allergy prevention | Thomas Wekerle |
2019 - 2022 | DOC (OEAW) | The role of MHC-specific IgE in antibody-mediated transplant rejection | Anna Weijler |
2019 - 2024 | WWTF | Combination cell therapy for immunomodulation in kidney transplantation | Thomas Wekerle |
2018 - 2022 | Austrian Science Fund (FWF) | Mechanisms of IL-2 induced Transplantation Tolerance | Nina Pilat-Michalek |
2017 - 2021 | Teva Pharmaceuticals Europe BV | HLA-specific IgE antibodies in organ transplantation (an invest. Initiated study) | Thomas Wekerle |